相关实验视频
Updated: Jun 21, 2025

09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.4K
MEK 抑制剂:对心血管疾病的有希望的向治疗
Khaled A K Mohammed1,2, Paolo Madeddu1, Elisa Avolio1
1Bristol Heart Institute, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Frontiers in cardiovascular medicine
|July 16, 2024
概括
用MEK抑制剂 (MEKI) 向RAS-RAF-MEK-ERK通路显示出治疗心血管疾病 (CVD) 的前景. 临床前研究表明MEKI.
科学领域:
- 生物医学研究的研究.
- 心血管科学 心血管科学
- 分子信号通道的分子信号通道.
背景情况:
- 心血管疾病 (CVD) 是全球死亡率和残疾的主要原因.
- RAS-RAF-MEK-ERK信号通路调节心血管平衡中的关键细胞过程.
- 这种途径的失调有助于心血管病理.
研究的目的:
- 探索RAS-RAF-MEK-ERK通路在心血管健康和疾病中的作用.
- 对心脏和血管疾病中ERK信号传递的当前知识进行审查.
- 讨论针对心血管疾病这种途径的新型治疗策略.
主要方法:
- 在心血管疾病动物模型中对MEK抑制剂 (MEKI) 的临床前研究的审查.
- 分析ERK信号在动脉样硬化,心肌梗塞,心脏缩,心力衰竭和大动脉动脉瘤中的作用.
- 讨论MEKI的治疗潜力,优势,挑战和未来方向.
主要成果:
- ERK信号传递对于维持心血管平衡至关重要.
- 异常的ERK信号传递与各种心血管疾病的发病有关.
- 临床前研究表明,MEKI可以减弱ERK激活并减轻心血管疾病的进展.
结论:
- 用MEK抑制剂向RAS-RAF-MEK-ERK通路代表了对心血管疾病的有希望的治疗策略.
- 进一步的研究和MEKI的临床开发是有必要的,以改善患者的治疗结果.
- 了解ERK信号传递的作用是开发有效心血管疾病治疗的关键.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
662
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
662
Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502

